The estimated Net Worth of Robert R. Tufts is at least $167 ezer dollars as of 27 September 2012. Robert Tufts owns over 28,500 units of Novabay Pharmaceuticals Inc stock worth over $166,992 and over the last 17 years Robert sold NBY stock worth over $0.
Robert has made over 7 trades of the Novabay Pharmaceuticals Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Robert exercised 28,500 units of NBY stock worth $15,960 on 27 September 2012.
The largest trade Robert's ever made was buying 67,500 units of Novabay Pharmaceuticals Inc stock on 31 October 2007 worth over $270,000. On average, Robert trades about 5,234 units every 48 days since 2007. As of 27 September 2012 Robert still owns at least 348,408 units of Novabay Pharmaceuticals Inc stock.
You can see the complete history of Robert Tufts stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is C/O NOVABAY PHARMACEUTICALS, INC., 5980 HORTON STREET, SUITE 550, EMERYVILLE, CA, 94608.
Over the last 18 years, insiders at Novabay Pharmaceuticals Inc have traded over $3,799,939 worth of Novabay Pharmaceuticals Inc stock and bought 24,568,662 units worth $26,237,091 . The most active insiders traders include Pharma (Singapore) Pte. Ltd..., Pioneer Pharma Holdings Ltd... és Pharma (Hong Kong) Co Ltd P.... On average, Novabay Pharmaceuticals Inc executives and independent directors trade stock every 57 days with the average trade being worth of $127,779. The most recent stock trade was executed by Paul E. Freiman on 11 May 2023, trading 858 units of NBY stock currently worth $411.
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Novabay Pharmaceuticals Inc executives and other stock owners filed with the SEC include: